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Introduction: Glioma cells exert influence over the tumor-microenvironment in part
through the release of extracellular vesicles (EVs), membrane-enclosed structures
containing proteins, lipids, and RNAs. In this study, we evaluated the function of Ras-
associated protein 27a (Rab27a) in glioma and evaluated the feasibility of assessing its
role in EV release in glioma cells in vitro and in vivo.
Methods: Rab27a was knocked down via a short hairpin RNA (shRNA) stably
expressed in mouse glioma cell line GL261, with a scrambled shRNA as control.
EVs were isolated by ultracentrifugation and quantified with Nanoparticle Tracking
Analysis (NTA) and Tunable Resistive Pulse Sensing (TRPS). CellTiter-Glo viability
assays and cytokine arrays were used to evaluate the impact of Rab27a knockdown.
GL261.shRab27a cells and GL261.shControl were implanted into the left striatum of
eight mice to assess tumor growth and changes in the tumor microenvironment.
Results: Knockdown of Rab27a in GL261 glioma cells decreased the release of small
EVs isolated at 100,000× g in vitro (p = 0.005), but not the release of larger EVs, isolated
at 10,000 × g. GL261.shRab27a cells were less viable compared to the scramble
control in vitro (p < 0.005). A significant increase in CCL2 expression in shRab27a
GL261 cells was also observed (p < 0.001). However, in vivo there was no difference
in tumor growth or overall survival between the two groups, while shRab27a tumors
showed lower proliferation at the tumor borders. Decreased infiltration of IBA1 positive
macrophages and microglia, but not FoxP3 positive regulatory T cells was observed.
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Conclusion: Rab27a plays an important role in the release of small EVs from glioma
cells, and also in their viability and expression of CCL2 in vitro. As interference in Rab27a
expression influences glioma cell viability and expression profiles, future studies should
be cautious in using the knockdown of Rab27a as a means of studying the role of small
EVs in glioma growth.
Keywords: glioma, glioblastoma, extracellular vesicles, exosomes, tumor microenvironment, Rab27a
INTRODUCTION
Glioblastoma (GB; WHO grade IV glioma) and lower grade
gliomas are known to manipulate and exploit the tumor-
microenvironment in the brain (Broekman et al., 2018). One
way in which the tumor interacts with the microenvironment
is via the secretion of extracellular vesicles (EVs). EVs are
membrane-enclosed structures that bud from the cell membrane
(microvesicles or ectosomes), or are released by fusion of multi-
vesicular endosomes (MVEs) with the plasma membrane (so-
called exosomes, or “small EVs”) (Maas et al., 2017). EVs contain
an assortment of proteins, lipids, and RNAs, roughly representing
the cytosol of the producer cell (Abels and Breakefield, 2016).
These EVs are secreted into the extracellular space and can
be transferred to adjacent and, to a lesser extent, distant cells
(Van Niel et al., 2018).
In GB, tumor-derived EVs have been shown to support
progression via several mechanisms. First of all, these EVs
help create an immune suppressed environment in the brain,
compounding to the already low intrinsic immunogenicity of
GB (Abels et al., 2019a). Glioma-derived EVs have been shown
to modify the phenotype of invading monocytes, macrophages,
and microglia, inducing tumor-supportive transcriptomic and
phenotypic changes in these cells (De Vrij et al., 2015; Van Der
Vos et al., 2016; Abels et al., 2019b). In addition to the effects
on the innate immune system, local as well as peripheral T-cell
activation is hindered by the expression of PD-L1 on GB-derived
EVs (Harshyne et al., 2016; Ricklefs et al., 2018). Furthermore,
GB-derived EVs have been shown to modify astrocytes toward
a tumor-supportive phenotype (Oushy et al., 2018; Hallal et al.,
2019). Glioma cells also use EVs to communicate amongst
themselves: oncogenic drivers can be exchanged, most well-
described for the Epidermal Growth Factor Receptor (EGFRvIII)
pathway (Al-Nedawi et al., 2008). In general, proliferation
and invasion is enhanced by GB EVs in vitro and in vivo,
although the exact mechanisms are not well understood (Skog
et al., 2008; Pinet et al., 2016). Finally, GB EVs contribute to
the typical aberrant neo-vascularization and increased vascular
permeability seen in GB, by containing various proteolytic
enzymes (Giusti et al., 2016), chemokine receptors (Treps et al.,
2016), pro-angiogenic growth factors (Treps et al., 2017), and
pro-angiogenic miRNAs (Lucero et al., 2020).
As the detrimental effects of tumor-derived EVs are being
revealed, efforts are being made to decrease the release of
EVs in various cancers (Bobrie et al., 2012; Datta et al., 2017;
Nishida-Aoki et al., 2017). In in vitro models, knockdown of
Ras-associated protein 27a (Rab27a), implicated as a driver in
exosome release, is a well-known method of decreasing release
of small EVs. Rab27a controls the fusion of MVEs to the plasma
membrane, initiating the release of small EVs (i.e., exosomes),
into the extracellular space (Ostrowski et al., 2010; Bobrie et al.,
2012). Knockdown of Rab27a has been shown to decrease the
shedding of small EVs in fibrosarcoma (Sung et al., 2015),
melanoma (Peinado et al., 2012), prostate (Webber et al., 2015),
and breast cancer (Bobrie et al., 2012) cell lines.
In this study, we sought to assess the role of Rab27a in
EV release in glioma. We show that knockdown of Rab27a
decreased release of small exosomes, as detected by Nanoparticle
Tracking Analysis (NTA) and Tunable Resistive Pulse Sensing
(TRPS). However, knockdown of Rab27a also had various off-
target downstream effects, hindering cell growth in vitro and
changing cytokine release. Knockdown of Rab27a did not affect
release of larger EVs. In vivo, no clear differences in tumor
growth were seen in a mouse syngeneic brain tumor model,
while changes in immune cell infiltration were observed. These
effects raise caution in interpreting effects of altering Rab27a
expression in studying the effects of exosome release in gliomas.
Furthermore, it encourages further research into the functions of
Rab27a in glioma and the role of other, larger, EVs in tumor-to-
microenvironment communication.
RESULTS
Rab27a Knockdown Decreases EV
Release
To knockdown Rab27a, we stably transduce GL261 cells with a
lentiviral vector bearing an expression cassette encoding a short
hairpin RNA (shRNA) targeting Rab27a mRNA. Our GL261 cell
line had previously been transduced to express Firefly luciferase
and GFP (GL261.Fluc.GFP) (Figure 1A). Three shRNAs were
tried, but only one showed consistent viability of the cells
(Supplementary Table 1). As a control, GL261.Fluc.GFP were
transduced with a non-targeting shRNA (shControl). Significant
Rab27a knockdown by over 70% was confirmed via RT-qPCR,
while expression of Rab27b was not affected (independent t-test:
p = 0.03 and p = 0.3, respectively; Figure 1B). Protein levels
of Rab27a were diminished after knockdown, as confirmed by
western blot (Figure 1C). EVs were isolated from culture media
using a differential ultracentrifugation protocol (Figure 1D)
(Théry et al., 2018). We opted to isolate and evaluate EVs
collected at 10,000 and 100,000 × g. The size of the EVs
was analyzed with two different characterization methods. NTA
detects and quantifies vesicles by illuminating the particles in
suspension with a laser and capturing the light scatter under
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FIGURE 1 | Effects of Rab27a knockdown on in vitro EV release. (A) Constructs used to transduce GL261 glioma cell line to create GL261.Fluc.GFP.shRab27a/
shControl. CMV, cytomegalovirus promoter; Fluc, firefly luciferase; IRES, internal ribosome entry site; GFP, green fluorescent protein; shRab27a, short hairpin
Ras-associated protein 27a; shControl, short hairpin control; hPGK, human phosphoglycerate kinase promoter. (B) mRNA expression of Rab27a and Rab27b,
shControl versus shRab27a, as determined by qPCR. Fold expression normalized to GAPDH mRNA, three replicates per condition. Mean with standard deviation
(SD), independent student t-test: *p < 0.03. (C) Western blot for Rab27a and β-actin in shControl versus shRab27a cells, in triplicate. kDa, kilo dalton. (D) Vesicle
isolation protocol via ultracentrifugation. (E) Vesicle size in nm as determined by nanoparticle tracking analysis (NTA) in 100,000 and 10,000 × g fractions. Mean with
SD. (F) Vesicle size in nm as determined by tunable resistive pulse sensing (TRPS) in 100,000 × g fraction. Mean with SD. (G) Vesicle count per cell as determined
by NTA in 100,000 and 10,000 × g fractions. Mean with SD, independent t-test: *p < 0.05. (H) Vesicle count per cell as determined by TRPS in 100,000 × g
fraction. Mean with SD, independent student-t test: **p < 0.01.
a microscope. A camera tracks the particles and using the
Stoke–Einstein equation the individual size of the particles is
calculated (Dragovic et al., 2011). NTA showed that the EVs in the
10,000 × g fraction were significantly larger compared to those
in the 100,000 × g fraction (independent t-test: p = 0.0003), and
that there was no difference in size between vesicles isolated from
GL261.shRab27a and GL261.shControl cells (Figure 1E). EVs
isolated at 100,000 × g were additionally profiled using TRPS.
TRPS quantifies particles by passing them through a nanopore
located in a non-conductive polyurethane membrane separating
two fluid cells. A flow of ions is induced across the membrane. As
a particle crosses this field it alters the flow of ions, creating a brief
resistive pulse from which the size of the particle can be deduced
(Roberts et al., 2010). TRPS confirmed the similar size of small
EVs between the shRab27a and the shControl cells isolated at
100,000× g (Figure 1F). In the 100,000× g fraction, the number
of EVs released per cell was significantly reduced in shRab27a
cells compared to the control (independent t-test, p = 0.038)
(Figure 1G). This decrease was not observed in the 10,000 × g
fraction. Again, TRPS confirmed the decrease in number of small
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EVs isolated at 100,000× g in shRab27a cells (independent t-test,
p < 0.01) (Figure 1H). These results show that downregulating
the expression of Rab27a reduced the number of small EVs
released per cell.
Knockdown of Rab27a Interferes With
Cell Viability in vitro
Since the docking of MVEs to the plasma membrane is part
of normal cell physiology, we also investigated if interference
in these pathways would alter cell viability. Cell viability was
assessed using the Cell Titer Glo assay which quantifies the
number of viable cells by metabolic activity based on ATP
levels (Zakowick et al., 2008). We detected a 40% decrease in
cell viability 24 h after plating the shRab27a cells compared
to the scrambled shControl (independent t-test: p = 0.048),
increasing to a 50% difference after 72 h (independent t-test:
p < 0.014) (Figure 2A). As dysregulation of cytokine release
plays an important part in glioma pathogenesis, we investigated
downstream effects of Rab27a knockdown by evaluating the
cytokine release in the media after 72 h (Supplementary
Figures 1A–C) (Zhu et al., 2012). The array showed a major
increase in expression of CC-chemokine ligand 2 (CCL-2), and
minor upregulation of other cytokines such as TIMP-1 and CCL5.
The stark increase in CCL2 peaked our interest, as it is essential
for regulating the regulatory T cell response and stimulating
immunosuppression in GB (Chang et al., 2016), and can promote
tumor invasiveness (Zhang et al., 2012), while inhibition of its
main receptor CCR2 reduces myeloid infiltration and improves
the effect of checkpoint inhibition in glioma (Flores-Toro et al.,
2020). RT-qPCR showed a nearly twofold upregulation of CCL2
mRNA in shRab27a glioma cells (independent t-test, p < 0.0001)
(Figure 2B). This shows that in addition to reducing secretion of
small EVs, the downregulation of Rab27a alters cell viability and
cytokine release from GL261 cells.
Assessment of Rab27a Knockdown
in vivo
To further assess the impact of Rab27a knockdown on GL261
glioma cells, we investigated the growth dynamics of the two
cell lines, stably transduced with lentivirus packaged with an
expression cassette for firefly luciferase (Fluc), in vivo. To this
end, we injected GL261 cells in the striatum of eight C57BL/6
mice: four with shRab27a cells, and four with shControl cells
(scrambled shRNA) (Figure 2C). Fluc was used to monitor the
growth of the tumor with in vivo bioluminescence imaging over
time (Supplementary Figure 1D). Endpoints where determined
as either a >20% decrease in body weight, presence of lethargy,
or debilitating neurological symptoms.
The tumor-derived Fluc signal decreased until day 12, after
which tumors in both groups showed exponential growth
(Figure 2D). This growth pattern is typical for implantations
with GL261 (Abdelwahab et al., 2011). There was no difference
in average size of tumors (as estimated by Fluc signal and
post-mortem gross pathology) or rate of tumor growth. After
40 days, all mice had reached their end-points. Mice implanted
with shRab27a GL261 tumors had a median survival of 24 days,
compared to 21 days in the control group (Figure 2E, log-rank
test: p = 0.35).
As we observed lower viability and cell growth for
GL261.shRab27a in vitro, we stained tumors for Ki-67, a
cell proliferation marker (Scholzen and Gerdes, 2000), after the
mice had reached their end-points (Figures 3A,B). Measuring
mean intensity in 10 randomly selected areas, we observed
a higher intensity for Ki-67 in the tumor core of shRab27a
(Figure 3C, independent t-test, p = 0.001), while intensity for
Ki-67 was higher in the tumor border of shControl tumors
(Figure 3D, independent t-test, p = 0.03). As CCL2 has been
implicated in recruitment of regulatory T cells (Chang et al.,
2016), we manually counted the number of FoxP3, a marker for
regulatory T cells (Li et al., 2015), positive cells in shControl and
shRab27a tumors. We found a slight increase in the number of
regulatory T cells in shRab27a tumors, but this difference was
not significant (Figures 3E–G).
Finally, we investigated changes in infiltration of microglia
and macrophages via staining with IBA-1 (Figures 3H–J)
(Ahmed et al., 2007). We performed an automated count of
the number of IBA-1 positive cells using ImageJ, randomly
selecting 11 areas for three different mice per condition (33
areas where counted in total per condition) (example shown in
Supplementary Figure 1E). Median number of IBA-1 positive
cells per area was 22 in the shRab27a group versus 29 in the
shControl group (Figure 3J, independent t-test, p = 0.006).
This finding was confirmed by a second researcher, blinded to
the previous outcome and nature of the tumors (560 µm by
290 µm, n = 15 per condition. Median IBA-1 positive cells in the
shRab27a group: 131 versus 185 in shControl group, p = 0.03.
Data not shown).
DISCUSSION
In this study, we confirmed the role of Rab27a in the release
of small EVs in glioma in vitro and showed that knockdown of
Rab27a resulted in reduced cell viability and increased expression
of CCL2. In vivo, growth of tumors and overall survival of
mice did not differ after implantation in the striatum, although
glioma cells showed higher proliferation at the tumor border
in the shControl tumors. Tumor infiltration of IBA-1 positive
cells was significantly decreased after Rab27a knockdown,
while infiltration of FoxP3 positive regulatory T cells showed
an upward trend.
The mechanisms by which EVs are released are multifold. In
broad terms, large EVs (microvesicles) are generally released by
budding off of the plasma membrane or nanotubules, while small
EVs (exosomes) are released through fusion of multivesicular
endosomes with the plasma membrane (Abels and Breakefield,
2016). While the importance of EVs in cancer progression
is becoming increasingly apparent (Sato and Weaver, 2018),
our understanding of the underlying molecular mechanisms
contributing to specific cargo packaging, vesicle release, and
modes of communication remains limited. Rab27a facilitates
docking of MVEs to the plasma membrane, one of the final
steps in exosome release (Ostrowski et al., 2010; Van Niel
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FIGURE 2 | Effects of Rab27 on tumor growth. (A) Cell viability as measured by Cell Titer Glow. shControl.GL261 versus shRab27a.GL261. Three replicates per
condition at three consecutive time points. P-values: *10.048, *20.045, *30.014. (B) Fold expression of Rab27a and CCL2 via qPCR, normalized to GAPDH. Mean
with SD, independent t-test: ***p < 0.001. (C) Schematic of tumor injection and time schedule. (D) Expression of firefly luciferase (Fluc) as an indicator of tumor size
was determined by in vivo imaging system (IVIS) in total flux per second from day 4 until day 28. Four mice per group. * indicates death or euthanasia of mice in
respective group. (E) Overall survival. End-point was defined as death, or euthanasia due to >20% decrease in weight, presence of lethargy, or debilitating
neurological symptoms. Four mice per group. Log-rank test: p = 0.35.
et al., 2018). Indeed, here we show that knockdown of Rab27a
decreased release of small EVs in glioma cells in culture, as
previously described for other cancer cell lines (Bobrie et al.,
2012; Peinado et al., 2012; Sung et al., 2015; Webber et al.,
2015). Although decreasing the release of EVs in general by
cancer cells might restrict tumor progression, it is important
to note that EVs are heterogeneous (Mathieu et al., 2019). EVs
produced by cancer cells contain specific proteins, RNAs, and
other molecules related to tumor growth and metastasis, and
there is increasing awareness that some EVs are packaged and
released via cancer specific mechanisms (Clancy et al., 2015;
Sato and Weaver, 2018). At least a subset of EVs released from
cancer cells have unique properties as compared to those from
normal cells. Guo et al. (2019) showed that small EVs isolated
by ultracentrifugation from melanoma cells with high Rab27a
expression contained much higher concentrations of proteins
related to cancer cell invasion and metastasis compared to
EVs isolated from human melanoma cells with loss of Rab27a
expression. Furthermore, decreased Rab27a expression in these
cells decreased invasion and cell motility in vitro and in vivo.
In vitro this could be partly rescued by adding small EVs isolated
from Rab27a expressing cells, while adding small EVs isolated
from Rab27a knockout cells did not have this effect. This suggests
that Rab27a has a role in regulating the types of EVs released
and their contents, enhancing their tumor stimulatory effects in
cancer cells. Currently, we could not evaluate the changes in EV
release in vivo in our model. We assume that the effects on vesicle
release observed in vitro mimic the effects in vivo, but in vivo
circumstances, such as hypoxia, cell stress, and necrosis could
be more dominant regulators of EV release (Caruso and Poon,
2018; Shao et al., 2018). Methods to evaluate EV release from
tumors in vivo (Van Der Vos et al., 2016), which are not yet
quantitative, could provide valuable insight into these processes.
Moreover, aside from the traditional methods of EV release,
cancer cells appear to have additional pathways for shedding
EVs. Oncosomes are larger vesicles, specifically found in cancers,
which bleb from the cell membrane (Minciacchi et al., 2015a,b).
In prostate cancer cells, oncosomes can be separated from small
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FIGURE 3 | In vivo characterization of tumors. All tumors were acquired after death from the tumor, or euthanasia due to >20% decrease in weight, presence of
lethargy, or debilitating neurological symptoms. (A) Representative immunohistochemical staining of GL261.shcontrol tumor and surrounding tissue. Red: Ki-67,
green: GFP, blue: DAPI. (B) GL261.shRab27a tumor. Red: Ki-67, green: GFP, blue: DAPI. (C) Ki-67 expression as measured by mean intensity per field of view in the
tumor core. Mean and standard error. Independent t-test: **p = 0.001. (D) Ki-67 expression as measured by mean intensity per field of view in the tumor border.
Mean and standard error. Independent t-test: *p = 0.03. (E) Representative immunohistochemical staining of GL261.shcontrol tumor border. Red: FoxP3, green:
GFP, blue: DAPI. (F) GL261.shRab27a tumor border. Red: FoxP3, green: GFP, blue: DAPI. (G) Number of FoxP3 positive cells per field of view. Mean and standard
error. NS, not significant. (H) Representative immunohistochemical staining of a GL261.shControl tumor and surrounding tissue. Red: IBA-1, blue: DAPI.
(I) GL261.shRab27a tumor. Red: IBA-1, blue: DAPI. (J) IBA-1 positive cells as counted per field of view in ImageJ. Mean and standard error. Independent t-test:
**p = 0.006.
EVs via discontinuous centrifugation gradient (Minciacchi et al.,
2015b). Treatment of these cells with oncosomes led to changes in
aspartate transaminase metabolism, while small EVs did not have
this effect (Minciacchi et al., 2015b). Apoptotic bodies, previously
considered as cell debris, have been implicated in various cancer
processes, ranging from immune modulation to stimulation of
tumor growth (Lynch et al., 2017; Caruso and Poon, 2018). More
nuance is needed in describing these various particles, as they
are hard to distinguish from one another and clear consensus on
defining features is currently lacking (Théry et al., 2018; Mathieu
et al., 2019). It could very well be that in vivo, additional cell
stress, caused by hypoxic conditions and necrosis, stimulates the
shedding of apoptotic bodies and/or oncosomes, compensating
for the signals lost due to Rab27a knockdown.
Previous work has shown that Rab27a plays an important role
in cell viability and proliferation in a range of cancers. Reduced
proliferation and invasion has been described in melanoma after
knockdown of Rab27a (Akavia et al., 2010; Guo et al., 2019), while
in breast cancer cell growth was decreased (Bobrie et al., 2012).
In bladder cancer, knockdown reduced invasion and high
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expression was corelated with poor prognosis (Ostenfeld et al.,
2014). This relation between high expression of Rab27a and
poor prognosis has been found in many cancers, such as lung
cancer (Koh and Song, 2019), melanoma (Akavia et al., 2010;
Guo et al., 2019), and hepatocellular carcinoma (Dong et al.,
2012). In glioma, there is an increasing body of research noting
the importance of Rab27a in viability and aggressiveness of these
tumors. In patients, increased Rab27a expression has been linked
to poorer survival and malignant progression of GB (Wang
et al., 2014). Recently, short hairpin mediated knockdown of
Rab27a in 73C glioma cells showed decreased growth in vitro and
in vivo in a mouse model (Gao et al., 2020). siRNA mediated
knockdown of Rab27a in C6 and U251 glioma cell lines has
also resulted in a decrease in cell proliferation and invasion (Liu
et al., 2012). Conversely, overexpression of Rab27a has been
shown to increase cell viability, proliferation, and invasion in
U251 cells (Wu et al., 2013). We observed a significant impact of
Rab27a on cell viability: shRab27a GL261 cells showed decreased
viability in vitro compared to the GL261 cells transduced with
a shControl. As the transduction itself did not interfere with
the phenotype or viability, with shControl cells showing similar
growth and viability compared to GL261 wild-type (data not
shown), it seems unlikely that this was the root of the decrease
in viability. In vivo, we observed a slight increase in expression of
proliferation marker Ki-67 in the core of shRab27a tumors, while
at the border Ki-67 intensity was weaker. As the tumor core in fast
growing tumors tends to be hypoxic and necrotic, it is possible
that the proliferation here decreases at the later stages of tumor
growth and that a faster growing tumor leads to less viable cells
in the tumor core. In patients, GB with significant necrosis on
MRI has been related to poorer outcomes and more aggressive
tumors (Hammoud et al., 1996). The infiltrating tumor cells at the
tumor border showed higher expression of Ki-67 in the control,
suggesting that shControl tumors have a slightly more aggressive
outward growth, corresponding to our data in vitro.
For our study, we focused on the effects of Rab27a in the
syngeneic GL261 mouse glioma model. We chose this model
because it has been extensively used in vivo and thoroughly
characterized (Szatmári et al., 2006). Furthermore, implantation
can be done in immunocompetent mice, allowing for analysis of
changes in the (immune) tumor microenvironment. More studies
are needed to address the role of Rab27a in glioma in different cell
lines and in vivo models. Interestingly, Gao et al. (2020) showed
a stark difference in tumor growth after Rab27a knockdown in
73C cells, noting a 30-fold decrease in vivo. This highlights the
fact that different glioma cell lines might respond differently to
knockdown of Rab27a, with some cell lines more affected than
others. The exact mechanisms underlying Rab27a expression
and cell viability in glioma and cancer in general remain to be
further understood.
We found that knockdown of Rab27a led to a marked increase
in expression of CCL2, a cytokine vital in mediating macrophage,
micoglia, and regulatory T cell infiltration in glioma (Chang et al.,
2016). We observed a decrease in IBA-1 positive cells in shRab27a
GL261 tumors, while infiltration of FoxP3 regulatory T cells was
slightly increased, albeit not significant. In mice, blocking of
CCL2 has been shown to increase the antiangiogenic effects of
bevacizumab (Cho et al., 2019). Knockdown of CCL2 via siRNA
inhibited cell proliferation and angiogenesis in the glioma cell
line U251 in vitro (Lu et al., 2017) while overexpression in a U87
glioma cell line increased invasiveness, dependent on presence
of CCR2-expressing microglia (Zhang et al., 2012). The decrease
in infiltration of IBA-1 cells in shRab27a tumors is therefore
surprising. EVs play a vital role in tumor to cell communication
(Van Der Vos et al., 2016; Broekman et al., 2018) and it was
recently shown that PD-L1 released via EVs is essential for
suppressing T cell activation in glioma (Poggio et al., 2019). It
could be possible that the decrease in EV release negates any
immune-stimulatory effects that the increase of CCL2 release
has on the tumor microenvironment. In our study, we did not
analyze the presence of PD-L1 in the 10.000 or 100.000 × g
fraction, so we were not able to address if EV mediated PD-L1
release was diminished. Another caveat is that we were not able
to quantify the levels of CCL2 in vivo, data that can be important
to elucidate whether the increase in vitro pertains in vivo. These
experiments should be done in future studies to further our
knowledge of the interaction between Rab27a and CCL2. The
underlying mechanisms are currently unclear and remain to be
further understood.
Recent in vitro work has shown that GB-derived vesicles can
modify the phenotype of monocytic cells, inducing expression
of EGFR and secretion of IL-6, increasing phagocytosis, and
reducing levels of c-Myc (De Vrij et al., 2015; Van Der Vos et al.,
2016). In our model, we saw that macrophage and microglial
infiltration was decreased after knockdown of Rab27a. However,
given the previously discussed impact of Rab27a knockdown on
CCL2 expression, this model may not be able to pin-point the
exact mechanisms to study glioma–macrophage interactions via
EVs. We also acknowledge that various factors can interfere with
accurate cell count, such as areas of necrosis, and further studies
need to be done to confirm this effect.
The problem of off-target effects of Rab27a knockdown has
been noted before. Peinado et al. (2012) found a decrease
in the secretion of various growth factors, such as placental
growth factor 2 (PlGF-2) and platelet-derived growth factor A
chain homodimer (PDGF-AA) after knockdown of Rab27a in
melanoma cells, and Bobrie et al. (2012) observed a decrease
in the release of matrix metalloproteinase 9 after knockdown of
Rab27a in HeLa cells. This further warrants caution in ascribing
observed effects to a decrease in the release of small EVs if
achieved via knockdown of Rab27a.
In summary, we showed that knockdown of Rab27a decreased
the release of small EVs, hampered viability of GL261 cells,
and increased secretion of the chemokine CCL2 in vitro.
In vivo, tumor growth and overall survival was not affected by
knockdown of Rab27a, but lower Ki-67 expression was observed
at the tumor border. Infiltration of IBA-1 positive macrophages
and microglia was decreased in GL261.shRab27a tumors, while
infiltration of FoxP3 regulatory T cells showed an upward trend.
The exact relation between Rab27a expression, EV release, cell
viability, and cytokine release needs to be further elucidated
before Rab27a can be used to study EVs in glioma biology or
used with therapeutic intent. New discoveries of ways in which
tumor cells release EVs, such as oncosomes and apoptotic bodies,
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underline the notion that interfering with a single mode of EVs
release might be of little therapeutic value in cancer.
MATERIALS AND METHODS
Cell Culture
Cell culture and viral transduction details can be found in the
Supplementary Methods.
Viability Assay
In a 96-well, 10,000 cells were plated per well and incubated
overnight at 37◦C in 5% CO2. CellTiter-Glo R© (Promega,
Madison, WI, United States) reagents were mixed and added to
the wells the after 24/48/72 h. After 2 min of mixing and 10 min
of incubation at room temperature, luminescence was recorded
on a Synergy HTX platform (BioTek Instruments, Winooski,
VT, United States).
Extracellular Vesicle Isolation
1.5 × 106 cells/dish were plated on 150 mm dishes. After 24 h,
the medium was removed, and the cells were incubated for 48 h
in 20 ml EV-depleted FBS supplemented medium [RPMI with
5% FBS (EV-depleted) + 1% penicillin/streptomycin + 2 µl/ml
puromycin]. FBS was depleted of EVs by 16-h ultracentrifugation
at 160,000 × g. Conditioned medium was then collected and
centrifuged according to the following protocol: 300 × g for
10 min, 2000 × g for 10 min both at room temperature, then
10,000 × g for 30 min at 4◦C (saving the pellet) followed by
centrifugation of the supernatant at 100,000 × g at 4◦C for
70 min. The last supernatant was then discarded, the pellet
resuspended, and again centrifuged at 100,000 × g at 4◦C for
70 min. The 10,000× g pellet and the final 100,000× g pellet were
isolated for EV analysis. The pellets were diluted 2× in 0.22 µm
filtered PBS (1%) and stored at −80◦C for RNA analysis. Vesicle
quantification and analysis was done directly after isolation.
Vesicle Quantification
Quantification of vesicles was performed using the NanoSight
LM10 NTA (Salisbury, Great Britain) with NTA 3.1 software.
Movies were captured for 30 s with settings (camera-level 12);
slider shutter 1187 and slider gain 286. For analysis, screen
gain was set at 10 and the detection threshold at 3.0. After
collection of the media, cells were trypsinized and counted by
hand to correct for the number of cells. The 100,000 × g
fractions were also quantified with TRPS using the qNANO
(Izon Science, Cambridge, MA, United States) and Izon Control
Suite 3.2 software. The NP200 (A30771) nanopore was used
with the following settings: applied stretch: 46.69 mm, applied
voltage: 0.46 V, average current: 112 nA, average noise: 9.6 nA,
maximum particle count: 500 particles, and maximum duration:
120 s. All samples were measured twice in separate blocks
according to the same settings. All samples were calibrated using
CPC200 calibration particles (Izon Science) in a 1:1000 dilution
in 2× 0.2 µm filtered PBS.
Western Blotting
Details can be found in the Supplementary Methods.
Quantitative Real-Time PCR
Details can be found in the Supplementary Methods.
Cytokine Array
300,000 cells were seeded in a six-well plate. 500 µl of media was
collected after 72 h. Samples were spun for 10 min at 300 × g
to remove any residual cells. The cytokine array was performed
using the Proteome Profiler Array Mouse Cytokine Array Panel
A (R&D Systems, Minneapolis, MN, United States), following
the manufacturer’s protocol. Quantification was done in ImageJ
using the Dot Blot Analyzer for ImageJ by Gilles Carpentier,
Universite de Paris, France (Carpentier, 2008).
Animal Care
C57BL/6 (Charles River Laboratories Wilmington, MA,
United States) aged between 8 and 12 weeks were used
for all experiments. Animals were housed at the animal
facility of the Massachusetts General Hospital under standard
laboratory conditions, with free access to water and food. After
injection of tumor cells, mice were monitored daily to assess
health, appearance and behavior. Mice were weighed three
times a week. All experiments were approved under IACUC
protocol 2009N000054.
Intracranial Tumor Cell Injections
C57BL/6 mice were anesthetized using isoflurane and their heads
secured in a stereotactic frame. A skin incision was made and
Bregma was localized. A burr-hole was made, and 100,000 cells
suspended in 2 µl OptiMEM (Thermo-Fisher, Waltham, MA,
United States) were injected at the estimated position of the left
striatum, 2.0 mm anterior and 0.5 mm lateral from Bregma,
2.5 mm deep from the skull surface. The incision was closed
with Hystoacryl glue (Braun) and a single dose of 100 µg/kg
buprenorphine (Temgesic, BD Pharmaceutical Ltd., Franklin
Lakes, NJ, United States) was administered as an analgesic. The
experimental group was injected with GL261.Fluc.GFP.shRab27a
cells, the control with GL261.Fluc.GFP.shControl cells. Endpoint
was either >20% weight loss or animal distress, at which time
mice were sacrificed.
Bioluminescence Imaging
100 µl D-Luciferin (Thermo-Fischer) (25 mg/ml in saline) was
injected intra-peritoneally in isoflurane-anesthetized mice. After
10 min, the mice were imaged using the IVIS (In Vivo Imaging
System) Spectrum connected to an X GI-8 Anesthesia System
(PerkinElmer, Waltham, MA, United States). Bioluminescence
was expressed as total flux per second.
Immunohistochemistry
Mice were perfused transcardial with PBS, followed by 4%
paraformaldehyde (PFA) (Electron Microscopy Sciences,
Hatfield, PA, United States). Brain were then removed and
stored in PFA overnight. After cryoprotection in 30% sucrose
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for 48 h, samples were frozen in NEG-50 (Thermo-Fischer)
at −80◦C. Brains were cut on a cryostat at 12 µm thickness.
For FoxP3, antigen retrieval was performed for 15 min in
boiling sodium citrate, 10 mM pH 6.0 + 0.5% Tween 20. For
staining, the sections were permeabilized with 0.5% Triton-X
in PBS for 1 h and blocked with 5% Normal Goat Serum
(Invitrogen, Carlsbad, CA, United States) for 1 h. Primary
staining was done overnight at 4◦, secondary for 1 h at room
temperature. Primary antibodies: Rabbit polyclonal IBA-1
(019-19741) antibody from Wako Chemicals (Richmond, VA,
United States) at 1:400, Ki67 (ab15580, Abcam, Cambridge,
United Kingdom) at 1:100, FoxP3 (D608R, Cell Signaling,
Danvers, MA, United States) at 1:100. Secondary: Alexa
Fluor 647 goat anti-Rabbit (A21245) (Invitrogen) at 1:1000.
Images were acquired on the Nikon Eclipse TE 2000-U (Nikon
Instruments Inc., Melville, NY, United States) and the BZ-X
microscope (Keyence, Itasca, IL, United States). ImageJ 2.0.0v
software was used to process the images and create Z-stacks.
Analysis was done with NIS-Elements v4.6 software (Nikon
Instruments Inc.) and ImageJ v2.0 (National Institutes of
Health, United States).
Cell Counting
Slides were stained for IBA-1 and DAPI and imaged as noted
above. The TRITC channel images were exported independently,
converted to black and white, and inversed. Eleven frames,
measuring 220 µm by 150 µm were selected at random within
a section of the tumor. Three different slides from three different
mice were used per condition. Using the ITCN plug-in version 1.6
(T. Kuo, J. Byun. Centre for Bio-Image informatics, University
of Santa Barbara) IBA1 positive cells were automatically
counted. A second, independent investigator blinded to the
study performed the analysis in similar fashion, using an area
measuring 560 by 390 µm on the same slides as the previous
researcher. An example is shown in Supplementary Figure 1D.
For FoxP3, 6 fields were randomly selected and cells were
counted manually in Adobe Photoshop (Adobe, San Jose, CA,
United States). For Ki-67, pictures were converted to grayscale
and 10 fields were randomly selected in the tumor center and
tumor border. Counting was done by hand and confirmed by an
independent investigator. Mean Gray Value was then calculated
in ImageJ.
Statistical Analysis
Individual statistical tests are noted in Section “Results” and
figure legends. Log-rank test was performed with Prism 8
(GraphPad Software, Inc., San Diego, CA, United States). All
other analyses were performed in R v3.4.1 (The R Foundation
for Statistical Computing). Graphs were made using Prism 8
(GraphPad Software). Independent t-tests were performed two-
tailed. P-values < 0.05 were considered as statistically significant.
Artwork
Illustrations used in Figure 1D were obtained from Servier
Medical Art (Les Laboratories Servier, France). Illustrations
used in Figure 2C were created with BioRender.com under the
Harvard license. Figures were made in Adobe Illustrator (Adobe,
San Jose, CA, United States).
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Supplementary Figure 1 | (A) Exploratory cytokine array, GL261.shRab27a on
the right, GL261.shControl on the left. (B) Quantification with the Dot Blot Analyzer
in ImageJ. (C) Signal intensity of cytokine array as measured with the Dot Blot
Analyzer. (D) Example of IVIS imaging at 16 days post tumor implantation. (E)
Example of cell count performed by ITCN-plugin in ImageJ. Image shows
shRab27a.GL261 tumor at 10×. Cut-out is shown of the counted area, red dots
mark cells counted by the software. In the cut-out, the red dots have been
highlighted in Adobe Illustrator for illustrative purposes.
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